Country: Canada
Language: English
Source: Health Canada
AMPRENAVIR
GLAXOSMITHKLINE INC
J05AE05
AMPRENAVIR
50MG
CAPSULE
AMPRENAVIR 50MG
ORAL
480
Prescription
HIV PROTEASE INHIBITORS
Active ingredient group (AIG) number: 0143241001; AHFS:
CANCELLED POST MARKET
2008-05-27
_DCTM/498/510/131-2005-06-21-pm-pristine--agenerase-capsules.doc _ _ _ _ _ _J_ _Appendix E - Product Monograph Template - Standard _ _Page 1 of 33_ PRODUCT MONOGRAPH Pr AGENERASE™ amprenavir 50 mg and 150 mg capsules Antiretroviral Agent GlaxoSmithKline Inc. 7333 Mississauga Road Mississauga, Ontario L5N 6L4 Date of Preparation: October 30, 2001 Date of Revision: June 27, 2005 Submission Control No: 097413 _©_ _ 2005 GlaxoSmithKline Inc. All Rights Reserved _ _™ AGENERASE used under license by GlaxoSmithKline Inc. _ _ _ _ _ _Appendix E - Product Monograph Template - Standard _ _Page 2 of 33_ Table of Contents PART I: HEALTH PROFESSIONAL INFORMATION.........................................................3 SUMMARY PRODUCT INFORMATION ........................................................................3 INDICATIONS AND CLINICAL USE..............................................................................3 CONTRAINDICATIONS ...................................................................................................3 WARNINGS AND PRECAUTIONS..................................................................................4 ADVERSE REACTIONS....................................................................................................9 DRUG INTERACTIONS ..................................................................................................12 DOSAGE AND ADMINISTRATION..............................................................................17 OVERDOSAGE ................................................................................................................19 ACTION AND CLINICAL PHARMACOLOGY ............................................................19 STORAGE AND STABILITY..........................................................................................21 SPECIAL HANDLING INSTRUCTIONS .......................................................................21 DOSAGE FORMS, COMPOSITION AND PACKAGING .............................................21 PART II: SCIENTIFIC Read the complete document